Shots:
- MiNA to receive $267.6M in up front, exclusivity fee on first neurological target and will be eligible to receive research, development, regulatory and commercial milestones along with royalties
- Servier will lead pre/ clinical development of lead candidates and will have the rights to commercialize any products that emerges from the collaboration
- The collaboration integrates Servier’s CNS expertise and MiNA’s small activating RNA technology to identify new potential treatments for restoring normal cell function in neurological disorders
Click here to read full press release/ article | Ref: Businesswire| Image: Nohat
The post Servier and MiNA Therapeutics Collaborate to Develop saRNA Therapies for Neurological Diseases first appeared on PharmaShots.
